CYTOKINETICS, INCORPORATED Other Comprehensive Income (Loss), Net of Tax
CYTOKINETICS, INCORPORATED (CYTK) reported Other Comprehensive Income (Loss), Net of Tax of $2.41 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-27.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTax · last filed 2025-02-27
- CYTOKINETICS, INCORPORATED other comprehensive income (loss), net of tax for the quarter ending 2024-12-31 was -$2.99M.
- CYTOKINETICS, INCORPORATED other comprehensive income (loss), net of tax for the quarter ending 2024-09-30 was $6.41M, a 997.43% increase year-over-year.
- CYTOKINETICS, INCORPORATED other comprehensive income (loss), net of tax for the quarter ending 2024-06-30 was -$483.00K, a 358.29% decline year-over-year.
- CYTOKINETICS, INCORPORATED other comprehensive income (loss), net of tax for the quarter ending 2024-03-31 was -$529.00K, a 127.20% decline year-over-year.
- CYTOKINETICS, INCORPORATED other comprehensive income (loss), net of tax for fiscal 2024 was $2.41M, a 32.74% decline from fiscal 2023.
- CYTOKINETICS, INCORPORATED other comprehensive income (loss), net of tax for fiscal 2023 was $3.58M.
- CYTOKINETICS, INCORPORATED other comprehensive income (loss), net of tax for fiscal 2022 was -$2.72M.
- CYTOKINETICS, INCORPORATED other comprehensive income (loss), net of tax for fiscal 2021 was -$1.02M.
| Period end | Other Comprehensive Income (Loss), Net of Tax 3 month | Other Comprehensive Income (Loss), Net of Tax 6 month | Other Comprehensive Income (Loss), Net of Tax 9 month | Other Comprehensive Income (Loss), Net of Tax 12 month |
|---|---|---|---|---|
| 2024-12-31 | -$2.99M derived: 10-K 12 month − 3 quarters · filed 2025-02-27 | $3.42M derived: sum of 2 quarters · filed 2025-02-27 | $2.94M derived: sum of 3 quarters · filed 2025-02-27 | $2.41M 10-K · filed 2025-02-27 |
| 2024-09-30 | $6.41M 10-Q · filed 2024-11-07 | $5.93M derived: sum of 2 quarters · filed 2024-11-07 | $5.40M derived: sum of 3 quarters · filed 2024-11-07 | |
| 2024-06-30 | -$483.00K 10-Q · filed 2024-11-07 | -$1.01M derived: sum of 2 quarters · filed 2024-11-07 | ||
| 2024-03-31 | -$529.00K 10-Q · filed 2024-11-07 | |||
| 2023-12-31 | $3.58M 10-K · filed 2025-02-27 | |||
| 2023-09-30 | $584.00K 10-Q · filed 2024-11-07 | $771.00K derived: sum of 2 quarters · filed 2024-11-07 | $2.72M derived: sum of 3 quarters · filed 2024-11-07 | |
| 2023-06-30 | $187.00K 10-Q · filed 2024-11-07 | $2.13M derived: sum of 2 quarters · filed 2024-11-07 | ||
| 2023-03-31 | $1.95M 10-Q · filed 2024-11-07 | |||
| 2022-12-31 | -$2.72M 10-K · filed 2025-02-27 | |||
| 2022-09-30 | -$1.06M 10-Q · filed 2023-11-03 | -$1.97M derived: sum of 2 quarters · filed 2023-11-03 | -$4.69M derived: sum of 3 quarters · filed 2023-11-03 | |
| 2022-06-30 | -$905.00K 10-Q · filed 2023-11-03 | -$3.63M derived: sum of 2 quarters · filed 2023-11-03 | ||
| 2022-03-31 | -$2.72M 10-Q · filed 2023-11-03 | |||
| 2021-12-31 | -$1.02M 10-K · filed 2024-02-28 | |||
| 2021-09-30 | -$43.00K 10-Q · filed 2022-11-04 | -$115.00K derived: sum of 2 quarters · filed 2022-11-04 | -$214.00K derived: sum of 3 quarters · filed 2022-11-04 | |
| 2021-06-30 | -$72.00K 10-Q · filed 2022-11-04 | -$171.00K derived: sum of 2 quarters · filed 2022-11-04 | ||
| 2021-03-31 | -$99.00K 10-Q · filed 2022-11-04 | |||
| 2020-12-31 | -$530.00K 10-K · filed 2023-03-01 | |||
| 2020-09-30 | -$379.00K 10-Q · filed 2021-11-05 | -$655.00K derived: sum of 2 quarters · filed 2021-11-05 | $279.00K derived: sum of 3 quarters · filed 2021-11-05 | |
| 2020-06-30 | -$276.00K 10-Q · filed 2021-11-05 | $658.00K derived: sum of 2 quarters · filed 2021-11-05 | ||
| 2020-03-31 | $934.00K 10-Q · filed 2021-11-05 | |||
| 2019-12-31 | $179.00K 10-K · filed 2022-02-25 | |||
| 2019-09-30 | -$42.00K 10-Q · filed 2020-11-06 | $113.00K derived: sum of 2 quarters · filed 2020-11-06 | $219.00K derived: sum of 3 quarters · filed 2020-11-06 | $272.00K derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-06-30 | $155.00K 10-Q · filed 2020-11-06 | $261.00K derived: sum of 2 quarters · filed 2020-11-06 | $314.00K derived: sum of 3 quarters · filed 2021-02-26 | $311.00K derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-03-31 | $106.00K 10-Q · filed 2020-11-06 | $159.00K derived: sum of 2 quarters · filed 2021-02-26 | $156.00K derived: sum of 3 quarters · filed 2021-02-26 | $117.00K derived: sum of 4 quarters · filed 2021-02-26 |
| 2018-12-31 | $53.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-26 | $50.00K derived: sum of 2 quarters · filed 2021-02-26 | $11.00K derived: sum of 3 quarters · filed 2021-02-26 | $157.00K 10-K · filed 2021-02-26 |
| 2018-09-30 | -$3.00K 10-Q · filed 2019-11-01 | -$42.00K derived: sum of 2 quarters · filed 2019-11-01 | $104.00K 10-Q · filed 2018-11-09 | |
| 2018-06-30 | -$39.00K 10-Q · filed 2019-11-01 | $107.00K derived: sum of 2 quarters · filed 2019-11-01 | ||
| 2018-03-31 | $146.00K 10-Q · filed 2019-11-01 | |||
| 2017-12-31 | $206.00K 10-K · filed 2019-03-07 | |||
| 2016-12-31 | -$12.00K 10-K · filed 2018-03-05 | |||
| 2015-12-31 | $153.00K 10-K · filed 2018-03-05 | |||
| 2014-12-31 | -$11.00K 10-K · filed 2017-03-06 | |||
| 2013-12-31 | -$11.00K 10-K · filed 2016-03-03 | |||
| 2012-12-31 | $15.00K 10-K · filed 2015-03-06 | |||
| 2011-12-31 | $7.00K 10-K · filed 2014-03-07 | |||
| 2010-12-31 | -$5.00K 10-K · filed 2013-03-15 | |||
| 2009-12-31 | -$17.00K 10-K · filed 2013-03-15 | |||
| 2008-12-31 | $19.00K 10-K · filed 2013-03-15 | |||
| 2007-12-31 | $74.00K 10-K · filed 2013-03-15 | |||
| 2006-12-31 | -$61.00K 10-K · filed 2013-03-15 | |||
| 2005-12-31 | $174.00K 10-K · filed 2013-03-15 | |||
| 2004-12-31 | -$234.00K 10-K · filed 2013-03-15 | |||
| 2003-12-31 | $6.00K 10-K · filed 2013-03-15 | |||
| 2002-12-31 | -$228.00K 10-K · filed 2013-03-15 | |||
| 2001-12-31 | $190.00K 10-K · filed 2013-03-15 | |||
| 2000-12-31 | $86.00K 10-K · filed 2013-03-15 | |||
| 1999-12-31 | -$8.00K 10-K · filed 2013-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 |